



Prereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed the Commissioner for Patents, Washington, D.C. 20231 on this 140 day of May 2002.

gnature of person mailing) Kelley D. Surprenant

MAY 1 3 2002

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CH CENTER 1600/2900

IN RE APPLICATION OF: N. Harper, et al.

APPLICATION NO.: 09/417,175

Examiner: T. Oh

Group Art Unit: 1623

FILING DATE: October 11, 1999

TITLE: Sertraline Oral Concentrate

Hon. Commissioner for Patents Washington, D.C. 20231

Sir:

PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. §1.136(a)

Pursuant to the provisions of 37 C.F.R. §1.136(a), it is requested that the term for response to the Examiner's Action in this application, mailed on November 6, 2001, and having an original period for response of three, which expired on February 6, 2002, be extended by three month(s), such that it expires on May 6, 2002.

Authorization is hereby provided to charge the amount of \$920.00 as stated under 37 C.F.R. §1.17, as well as any additional fees required, or to credit any overpayment to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Respectfully submitted,

Martha A. Gammill

Attorney for Applicant(s)

Reg. No. 31,820

Pfizer Inc. Patent Department, MS 8260-1611 Eastern Point Road Groton, Connecticut 06340

(860) 441-5940

05/10/2002 RMEBRAHT 00000059 161445 09417175

01 FC:117

920.00 CH